RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $136
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained a Sector Perform rating on Neurocrine Biosciences but lowered its price target from $143 to $136.
August 29, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital has maintained a Sector Perform rating on Neurocrine Biosciences but lowered its price target from $143 to $136, indicating a slightly less optimistic outlook.
The lowering of the price target by RBC Capital suggests a less optimistic view on the stock's potential, which could lead to a short-term negative impact on NBIX's stock price. The maintained Sector Perform rating indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100